Dr. Lulla Discusses Post-Transplant Options for Leukemias

Premal Lulla, MD
Published: Saturday, Feb 23, 2019



Premal Lulla, MD, assistant professor of medicine at the Center for Cell and Gene Therapy, Texas Children's Hospital, discusses the need for cellular therapies for patients with leukemia after transplant.

Patients who relapse posttransplant have a very poor prognosis, says Lulla. In this setting, there are no approved treatment options in the frontline setting.

Lulla believes the posttransplant environment has room for immunotherapy to improve outcomes. 

<<< 2019 Transplantation and Cellular Therapy Meetings


Premal Lulla, MD, assistant professor of medicine at the Center for Cell and Gene Therapy, Texas Children's Hospital, discusses the need for cellular therapies for patients with leukemia after transplant.

Patients who relapse posttransplant have a very poor prognosis, says Lulla. In this setting, there are no approved treatment options in the frontline setting.

Lulla believes the posttransplant environment has room for immunotherapy to improve outcomes. 

<<< 2019 Transplantation and Cellular Therapy Meetings

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x